anti-Hepatic Leukemia Factor (HLF) Anticorps

Mouse (Murine) Hepatic Leukemia Factor (HLF) interaction partners

1. HLF-deficient hematopoietic stem cells display loss of quiescence and increased sensitivity to chemotoxic insults.

2. Results demonstrate that Hlf is a genetic modifier of epilepsy caused by voltage-gated sodium channel mutations and that modulation of the pyridoxine pathway can also influence phenotype severity

3. Conditional expression of E2A (Montrer TCF3 Anticorps)-HLF induces B-cell precursor death and myeloproliferative-like disease in knock-in mice.

4. Data indicate that Meis homeobox 1 (MEIS1 (Montrer MEIS1 Anticorps)) is required for the maintenance of myeloid-lymphoid leukemia protein MLL (Montrer MLL Anticorps)-fusion gene leukemia, and hepatic leukemia factor (HLF)is a key downstream mediator of Meis1 (Montrer MEIS1 Anticorps).

5. we demonstrate that D site albumin promoter binding protein/thyrotroph embryonic factor (Montrer TEF Anticorps)/hepatic leukemia factor triple knockout mice develop cardiac hypertrophy and left ventricular dysfunction associated with a low blood pressure

6. mice deficient for all three PAR (Montrer AFG3L2 Anticorps) bZip proteins (DBP (Montrer GC Anticorps),HLF,& TEF (Montrer TEF Anticorps)) are highly susceptible to generalized spontaneous and audiogenic epilepsies, frequently lethal. Pyridoxal kinase (Montrer PDXK Anticorps) is a target gene of PAR (Montrer AFG3L2 Anticorps) bZip proteins in both liver and brain

7. The HLF protein control the expression of many enzymes and regulators involved in detoxification and drug metabolism, such as cytochrome P450 (Montrer CYP Anticorps) enzymes, carboxylesterases, and constitutive androstane receptor (Montrer NR1I3 Anticorps) (CAR).

8. Data show that the clock knockout mice or mice devoid of dbp (Montrer GC Anticorps)/hlf/tef (Montrer TEF Anticorps) (triple knockout) exhibit significant changes in renal expression of several key regulators of water or sodium balance.

Human Hepatic Leukemia Factor (HLF) interaction partners

1. Poly (ADP-ribose) polymerase (Montrer PARP1 Anticorps) inhibitors selectively induce cytotoxicity in TCF3 (Montrer TCF3 Anticorps)-HLF (Montrer EPAS1 Anticorps)-positive leukemic cells.

2. HLF-mediated miR-132 directly suppresses TTK expression, thus exerting inhibitory effects on cancer cell proliferation, metastasis and radioresistance.

3. Drug response profiling of matched patient-derived xenografts revealed a distinct profile for TCF3 (Montrer TCF3 Anticorps)-HLF (Montrer EPAS1 Anticorps) ALL with resistance to conventional chemotherapeutics but sensitivity to glucocorticoids.

4. ectopic expression of HLF (Montrer EPAS1 Anticorps), an established transcription factor that cycles with circadian rhythms, can recapitulate many features associated with circadian-dependent physiological variation.

5. both Lmo2 (Montrer LMO2 Anticorps) and Bcl-2 (Montrer BCL2 Anticorps) are required for the action of E2A (Montrer TCF3 Anticorps)-HLF (Montrer EPAS1 Anticorps) in leukemogenesis

6. E2A (Montrer TCF3 Anticorps)-HLF (Montrer EPAS1 Anticorps) promotes cell survival of t(17;19)- acute lymphoblastic leukemia cells by aberrantly up-regulating LMO2 (Montrer LMO2 Anticorps) expression

7. Evidence pertaining to leukemogenesis by the well-characterized oncogenic fusion protein E2A (Montrer TCF3 Anticorps)-HLF (Montrer EPAS1 Anticorps) is reviewed and its mechanistic implications are considered.

8. E2A-HLF induces annexin II by substituting for cytokines that activate downstream pathways of Ras

9. The E2A (Montrer TCF3 Anticorps)-HLF (Montrer EPAS1 Anticorps)-mediated over-expression of ABCB1 (Montrer ABCB1 Anticorps) may play a role in the clinical phenotype of ALLs with a t(17;19), suggesting pharmacologic modulation of ABCB1 (Montrer ABCB1 Anticorps) activity as a rational therapeutic strategy for this chemotherapy resistant subtype of ALL.

10. The patients with immunophenotype of Pre-B-acute lymphoblastic leukemia were found to carry: E2A (Montrer TCF3 Anticorps)/PBX1 (Montrer PBX1 Anticorps) and E2A (Montrer TCF3 Anticorps)/HLF (Montrer EPAS1 Anticorps).